New triple therapy shows promise for tough rectal cancers
NCT ID NCT07527520
First seen Apr 18, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a new approach for people with a high-risk type of rectal cancer. It combines a shorter course of radiation with chemotherapy and an immunotherapy drug (serplulimab). The goal is to see if this combination works better than standard treatment at shrinking or eliminating the tumor before surgery. About 165 adults with a specific genetic profile (pMMR/MSS) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hosptial, Fudan University
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.